SPORANOX
LOE ApproachingNDAORALSOLUTIONPriority Review
Approved
Feb 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
SPORANOX by Johnson & Johnson is mechanism of action in vitro studies have demonstrated that itraconazole inhibits the cytochrome p450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes. Approved for the following fungal infections in immunocompromised, non-immunocompromised patients: blastomycosis, pulmonary and 11 more indications. First approved in 1997.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPORANOX is an oral antifungal solution approved in 1997 containing itraconazole, a triazole that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase. It is indicated for systemic fungal infections including aspergillosis, blastomycosis, and histoplasmosis in immunocompromised patients.
$0.197MPart D
LOE ApproachingMature product approaching loss of exclusivity with minimal Part D spending (~$197K) suggests small, specialized sales team focused on niche indications.
Mechanism of Action
Mechanism of Action In vitro studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes.
Worked on SPORANOX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.